Format

Send to

Choose Destination
See comment in PubMed Commons below
J Thorac Cardiovasc Surg. 2016 Apr;151(4):1014-22, 1023.e1-3. doi: 10.1016/j.jtcvs.2015.10.070. Epub 2015 Oct 28.

Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: A randomized trial of a self-expanding prosthesis.

Author information

1
Cardiovascular Research Institute, University of Kansas Hospital, Kansas City, Kan. Electronic address: gzorn@kumc.edu.
2
Houston Methodist DeBakey Heart and Vascular Center, The Houston Methodist Hospital, Houston, Tex.
3
Cardiovascular Research Institute, University of Kansas Hospital, Kansas City, Kan.
4
University of Michigan Medical Center, Ann Arbor, Mich.
5
University of Pittsburgh School of Medicine, Pittsburg, Pa.
6
Spectrum Health Hospitals, Grand Rapids, Mich.
7
Mayo Clinic, Rochester, Minn.
8
Beth Israel Deaconess Medical Center, Boston, Mass.
9
Mount Sinai Medical Center, New York, NY.
10
Medtronic, Minneapolis, Minn.

Abstract

OBJECTIVES:

We compared the incidence of prosthesis-patient mismatch (PPM) between transcatheter aortic valve replacement (TAVR) using a self-expanding bioprosthesis and surgical aortic valve replacement (SAVR) in the CoreValve US High Risk Pivotal Trial. We sought to determine the influence of PPM on clinical outcomes.

METHODS:

Patients with severe aortic stenosis and at increased risk for surgery were randomized 1:1 to TAVR or SAVR. Postoperative PPM was defined by the effective orifice area index (EOAi) as severe PPM (EOAi ≤ 0.65 cm(2)/m(2)) and no severe PPM (EOAi > 0.65 cm(2)/m(2)); clinical outcomes were analyzed in the TAVR arm (n = 389) and SAVR arm (n = 353). Left ventricular mass index and regression were analyzed at baseline and 1 year.

RESULTS:

The incidence of severe PPM in the SAVR group at 1 year was 25.7% versus 6.2% in the TAVR group (P < .0001). Left ventricular mass index regression at 1 year was 6.8% for TAVR and 15.1% for SAVR in patients with severe PPM. At 1 year the rate of all-cause mortality and acute kidney injury were significantly greater in all patients (TAVR + SAVR) with severe PPM compared with no severe PPM (20.6% vs 12.0% [P = .0145] for death and 19.2% vs 8.5% [P = .0008] for acute kidney injury).

CONCLUSIONS:

In patients with high surgical risk and severe aortic stenosis, severe PPM is more common in patients treated with SAVR than those treated with TAVR. Patients with severe PPM are a greater risk for death and acute kidney injury than patients without severe PPM.

KEYWORDS:

aortic stenosis; prosthesis-patient mismatch; transcatheter aortic valve replacement

PMID:
26614412
DOI:
10.1016/j.jtcvs.2015.10.070
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center